Regardless, these results point to the potential of targeting KDM6A in overcoming resistance of CML to TKIs, in particular, when the resistance is conferred by NGF signaling. The gene discussed is KDM6A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.